Pfizer’s PF-06410293, a proposed biosimilar adalimumab referencing Humira, shares similar efficacy, safety, and immunogenicity profiles with its reference at 26 weeks of treatment, new research reports.
Pfizer’s PF-06410293, a proposed biosimilar adalimumab referencing Humira, shares similar efficacy, safety, and immunogenicity profiles with its reference at 26 weeks of treatment, new research reports.
The 26-week study results, published in Arthritis Research and Therapy, are part of a 78-week, double-blind, multicenter, randomized study comparing the proposed biosimilar with EU-licensed Humira in 597 biologic-naïve patients with active rheumatoid arthritis that has not responded adequately to methotrexate. Patients were randomized to receive 40 mg of either PF-06410293 (n = 297) or the reference product (n = 300) every other week for 26 weeks in the first treatment period.
Click to read more about the adalimumab biosimilar pipeline.
The study’s primary end point was the proportion of patients reaching the American College of Rheumatology’s criteria for 20% improvement (ACR20) at week 12, which the investigators say is a sensitive timepoint for assessment of the speed of response as it represents the start of the plateau of the time-response curve for ACR20.
The 26-week period of initial treatment was completed by 286 patients in the biosimilar arm and 273 patients in the reference arm. In the biosimilar arm, 68.7% of patients achieved ACR20, as did 72.7% of patients in the reference arm; the treatment difference was −3.98%, which was contained within the prespecified equivalence margin of ±14%.
ACR20, 50, and 70 rates were similar through week 26 for both groups, as were mean changes from baseline in disease activity score in a count of 28 joints with C-reactive protein, as well as European League Against Rheumatism response rates and decrease from baseline in Health Assessment Questionnaire Disability Index scores.
A total of 143 patients (48.1%) in the biosimilar arm and 143 patients (47.8%) in the reference arm reported at least 1 treatment-emergent adverse event (TEAE), with infections and infestations being the most commonly reported for both arms. Serious AEs were reported by 4.0% and 4.3% of patients in the respective arms, including 1 death due to myocardial infarction in the reference arm.
Hypersensitivity-related TEAEs were reported in 4.4% of the biosimilar arm versus 8.4% of the reference arm, with the most frequently reported hypersensitivity reactions comprising cough, erythema, and rash.
In total, 44.4% of patients in the biosimilar arm and 50.5% of patients in the reference arm had at least 1 postdose blood sample that tested positive for antidrug antibodies (ADAs). The mean serum drug trough concentrations at week 26 were 8244 and 7190 ng/mL in the biosimilar and reference arms, respectively, and mean serum concentrations were lower in both arms in patients who had ADAs.
The authors of the study concluded that these 26-week results suggest that there is no clinically meaningful difference in safety, efficacy, immunogenicity, pharmacokinetics, or pharmacodynamics between the proposed biosimilar and its reference. Further results from the study—which involve rerandomization of patients in the reference arm at week 26 to either continue receiving the reference or switch to the proposed biosimilar, as well as a switch of all remaining patients in the reference-only arm to the biosimilar at week 52—are forthcoming.
Reference
Fleischmann RM, Alten R, Pileckyte M, et al. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira) in the treatment of active rheumatoid arthritis. Arthritis Res Ther. 2018;20(1):178. doi: 10.1186/s13075-018-1676-y.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5
March 9th 2024The adalimumab biosimilar SB5 was reported to be as safe and effective as the reference product in a review of randomized controlled trials and real-world studies on immune-mediated inflammatory diseases.